Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)- Insider Own42.27% Shs Outstand37.19M Perf Week2.69%
Market Cap1.32B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float21.47M Perf Month-4.36%
Income- PEG- EPS next Q-0.50 Inst Own81.80% Short Float15.36% Perf Quarter110.74%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio9.72 Perf Half Y52.29%
Book/sh8.08 P/B4.40 EPS next Y- ROA- Short Interest3.30M Perf Year-
Cash/sh11.37 P/C3.12 EPS next 5Y- ROE- 52W Range14.19 - 38.06 Perf YTD27.17%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-6.66% Beta-
Dividend TTM- Quick Ratio24.81 Sales past 5Y- Gross Margin- 52W Low150.39% ATR (14)1.79
Dividend Ex-Date- Current Ratio24.81 EPS Y/Y TTM- Oper. Margin- RSI (14)57.67 Volatility4.16% 5.61%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price42.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-1048.60% Payout- Rel Volume1.73 Prev Close34.80
Sales Surprise- EPS Surprise-18.35% Sales Q/Q- EarningsNov 14 AMC Avg Volume339.32K Price35.53
SMA200.76% SMA5010.57% SMA20047.10% Trades Volume586,085 Change2.10%
Date Action Analyst Rating Change Price Target Change
Dec-20-23Initiated BTIG Research Buy $43
Aug-08-23Initiated Wedbush Outperform $40
Aug-08-23Initiated TD Cowen Outperform
Aug-08-23Initiated Stifel Buy $34
Aug-08-23Initiated Jefferies Buy $29
Aug-08-23Initiated Guggenheim Buy $29
Jan-02-24 07:30AM
Nov-15-23 04:44AM
Nov-13-23 07:30AM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
08:42AM Loading…
Sep-27-23 08:42AM
Sep-14-23 07:30AM
Aug-29-23 08:00AM
Aug-28-23 07:30AM
Aug-21-23 07:30AM
Aug-10-23 02:29PM
Aug-08-23 10:02AM
Aug-07-23 07:30AM
Aug-04-23 06:30PM
Aug-02-23 07:30AM
04:01PM Loading…
Jul-18-23 04:01PM
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorJul 13Buy17.002,941,17649,999,9921,992,734Jul 17 08:00 PM
Shah Nimish PDirectorJul 13Buy17.001,750,00029,750,0001,750,000Jul 17 08:00 PM